钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂的研究进展

Advances in the research of sodium-dependent glucose cotransporter 2 inhibitors

钠-葡萄糖协同转运蛋白2(SGLT2)是最近新发现的糖尿病治疗新靶点,其作用机制是特异性地抑制肾脏对葡萄糖的再吸收,且不依赖于β细胞的功能异常或胰岛素抵抗的程度。其效果也不会随着β细胞功能的衰竭或严重胰岛素抵抗而下降,不会产生传统药物带来的不良反应,是糖尿病治疗的新途径。本文介绍SGLT2在调节体内糖平衡中的作用,总结SGLT2抑制剂在2型糖尿病治疗方面的最新进展,并对已报道的抑制剂化学结构进行总结。

Sodium dependent glucose cotransporter 2 is a new target for the treatment of diabetes.Its mechanism is the inhibition of reabsorption of glucose in kidney,regardless of the nature of β cells,such as insulin resistance and function exhaustion.The inhibition of SGLT2 does not lead to side effects,which always observed with traditional drugs,and it is a new approach for developing antidiabetis agents.In this paper,the mechanism,structure and activity relationship and new progress of SGLT2 inhibitors are reviewed.